NCT06666049 Gastric POCUS for Airway Management in Patients Using Glucagon-like Peptide-1 Receptor Agonist (Multicentric)
| NCT ID | NCT06666049 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
| Condition | Aspiration Pneumonia |
| Study Type | OBSERVATIONAL |
| Enrollment | 39 participants |
| Start Date | 2024-10-21 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 39 participants in total. It began in 2024-10-21 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1\. Introduction Scheduled surgery requires patients to undergo a preoperative fasting period of at least 6 hours to reduce the risk of perioperative pulmonary aspiration. However, certain medications and conditions may delay gastric emptying, potentially increasing aspiration risk. These include diabetic gastroparesis and the use of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of diabetes and obesity. GLP-1 receptor agonists are widely used due to their beneficial effects on glycemic control and weight reduction. However, one of their known effects is delayed gastric emptying, which may result in increased residual gastric content despite adherence to standard fasting guidelines. Recent reports have described cases of pulmonary aspiration during anesthesia in patients receiving GLP-1 receptor agonists, even after appropriate fasting. Given the increasing use of these medications, there is a need for objective assessment tools to evaluate gastric content in the perioperative setting. Gastric ultrasonography has emerged as a non-invasive bedside technique that may help identify patients at increased risk of aspiration and guide airway management strategies.
Eligibility Criteria
Inclusion Criteria: Adults patients ,ASA I-III, taking GLP-1 analog medications, undergoing scheduled surgery. Exclusion Criteria: 1. \- History of esophagogastric pathology or previous abdominal surgery. 2. \- Hiatal hernia/gastroesophageal reflux disease. 3. \- Autonomic nervous system disorders. 4. \- Neurological or neuromuscular diseases. 5. \- Use of medications/drugs that affect autonomic regulation and delay gastric emptying (opioids) or potentiate it (prokinetics). 6. \- Pregnancy. 7. \- Presence of arrhythmias.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06666049 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Aspiration Pneumonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06666049 currently recruiting?
Yes, NCT06666049 is actively recruiting participants. Contact the research team at cpuga@unav.es for enrollment information.
Where is the NCT06666049 trial being conducted?
This trial is being conducted at Madrid, Spain, Salamanca, Spain.
Who is sponsoring the NCT06666049 clinical trial?
NCT06666049 is sponsored by Clinica Universidad de Navarra, Universidad de Navarra. The trial plans to enroll 39 participants.